BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld Asia
Home
» Intercell Gets $9.5M Up Front In Potential $85M Merck Deal
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Intercell Gets $9.5M Up Front In Potential $85M Merck Deal
Nov. 8, 2006
By
Cormac Sheridan
No Comments
Intercell AG earned an up-front payment of $9.5 million and could receive up to $76 million more in milestones from an agreement with Merck Sharpe & Dhome Research Ltd., an arm of Merck & Co. Inc. (BioWorld International)
BioWorld Asia